| payload |
{"created_at":"2026-04-08T11:43:27.727 {"created_at":"2026-04-08T11:43:27.727928+00:00","signal_type":"news_headline_delta","source":"news_rss","url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE5Cc2hXbUItSXhSYWJ2UlQ4RDAtS045Q2MzUlNTV0pMalpOVXZGNzgtVmxINGdGcV9JT1V0eW5zTDZBZFM3eXBlcmRzTTlnR05CT28zOE5iVzVDOE93T3k4?oc=5","value":{"fp":"ebb9e2c7f5615da0","published_at":"2026-04-08T01:08:37+00:00","source":"Nature","source_domain":"nature.com","source_url":"https://www.nature.com","summary":"New drugs take aim at one of cancer\u2019s deadliest mutations Nature Setidegrasib in Advanced NSCLC and Pancreatic Cancer Harboring the KRAS p.G12D Variant ascopost.com Breakthrough drugs could finally tackle deadliest \u2018undruggable\u2019 cancer mutation The News International Erika Hamilton on Advancing KRAS G12D Targeting in Lung and Pancreatic Cancer Oncodaily Florida Cancer Specialists & Research Institute Contributes to Phase 1 Study Demonstrating Antitumor Activity with First-in-Class KRAS-Targeted Therapy for Treatment of Lung and Pancreatic Cancers PR Newswire","title":"New drugs take aim at one of cancer\u2019s deadliest mutations - Nature","url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE5Cc2hXbUItSXhSYWJ2UlQ4RDAtS045Q2MzUlNTV0pMalpOVXZGNzgtVmxINGdGcV9JT1V0eW5zTDZBZFM3eXBlcmRzTTlnR05CT28zOE5iVzVDOE93T3k4?oc=5"}}... |